| Literature DB >> 34909309 |
Mahreen Saeed1, Moeez Ali2, Tehreem Zehra3, Saiyed Ali Haider Zaidi4, Rihab Tariq1.
Abstract
Type 2 diabetes mellitus (T2DM) is an alarmingly rising disorder characterized mainly by insulin resistance and hyperglycemia. Due to the impairment of glucose homeostasis, most subjects present with elevated serum glucose levels, which can lead to several complications, including hospitalizations and even death. Diet quality and quantity are at the heart of its pathogenesis; hence, for the management of this condition, a technique known as intermittent fasting (IF) has been an area of interest for researchers. Different fasting regimens, including alternate-day fasting, religious fasting, and time-restricted fasting, have proven to be of strategic importance for glycemic control due to their physiologic effects. According to case studies and randomized trials, therapeutic fasting has been shown to reverse insulin resistance, resulting in the discontinuance of insulin therapy while maintaining blood sugar levels. Studies on IF have demonstrated their efficacy in glycemic control and other metabolic parameters, including reducing visceral fat and controlling inflammatory mediators and markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), but control in obesity is its most significant effect as it acts as a risk factor for T2DM. Several case studies have shown a reduction in elevated hemoglobin A1c (HbA1c) levels in subjects after fasting, which some believe is due to sirtuin-6 (SIRT6) proteins. SIRT6 proteins are believed to be responsible for blood glucose homeostasis and insulin resistance reversal by increasing its sensitivity. This family of proteins is increased after fasting; hence, further research in this area will help researchers better understand its mechanism of action and potential therapeutic effects on T2DM. With an alarming increase in the incidence of T2DM around the world, a cost-effective strategy is required to control the disease with easy patient compliance, and IF might prove to be the solution.Entities:
Keywords: fasting; glycated hemoglobin (hba1c); intermittent fasting; religious fasting; therapeutic fasting; type 1 diabetes mellitus; type 2 diabetes mellitus; weight loss and obesity
Year: 2021 PMID: 34909309 PMCID: PMC8653959 DOI: 10.7759/cureus.19348
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Types of fasting and their structure
| Type | Fasting regimen |
| Alternate-day fasting regimen | Comprises alternate eating days (ad libitum consumption of food and beverages) with alternating fasting days (abstaining from energy-providing food and beverages) |
| Time-restricted food consumption | Ad libitum food intake at different intervals in a particular time frame |
| Modified fasting regimen | Permits ad libitum eating five days of the week and restricting food in the remaining two to only 20%–25% of energy requirement |
| Religious fasting | A fast practiced by Muslims in their holy month of Ramadan starting a little before sunrise to sunset. Eating is permitted before their morning prayer time and after the sunset. Thus, the average Ramadan fasting time around the world is about 12 hours |
| Other religious fasting | Fasting practices for religious or spiritual purposes |
Patient details and characteristics
T2D: type 2 diabetes; HTN: hypertension; CKD: chronic kidney disease; RCC: renal cell carcinoma
| Sex | Age | Onset of T2D | History/comorbidities | Fasting regimen | |
| Patient 1 | Male | 40 | Present; 20 years prior | HTN, hypercholesterolemia | Three times/week for seven months |
| Patient 2 | Male | 52 | Present; 25 years prior | CKD, RCC (nephrectomy in 2004), HTN, hypercholesterolemia | Three times/week for 11 months |
| Patient 3 | Male | 67 | Present; 10 years prior | HTN, hypercholesterolemia | Alternating days for 11 months |
Glycemic and other changes noted on patient follow-up
IU: international units
| Initial HbA1c (%, mmol/mol) | Final HbA1c (%, mmol/mol) | Initial weight (kg) | Final weight (kg) | Initial diabetic medications | Final diabetic medications | Time to discontinuation of insulin (days) | |
| Patient 1 | 11, 96.7 | 7, 53 | 83.8 | 73.8 | Insulin glargine 58, insulin aspart 22, canagliflozin 300 mg, metformin 1 g | Canagliflozin 300 mg | 5 |
| Patient 2 | 7.2, 55.2 | 6, 42.1 | 61 | 50.4 | Insulin lispro mix 25–38/32 IU 25 | None | 18 |
| Patient 3 | 6.8, 50.8 | 6.2, 44.3 | 97.1 | 88.1 | Metformin 1000 mg, insulin lispro mix 25–30/20 IU | None |